---
title: "J.P. Morgan Sticks to Its Buy Rating for First Tracks Biotherapeutics Inc (TRAX)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287441580.md"
description: "J.P. Morgan analyst Anupam Rama has maintained a Buy rating for First Tracks Biotherapeutics Inc (TRAX) with a price target of $30.00, while the stock closed at $17.18. The analyst consensus is a Strong Buy with an average price target of $38.33, indicating a potential upside of 123.11%. Barclays also holds a Buy rating with a $40.00 target."
datetime: "2026-05-23T12:27:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287441580.md)
  - [en](https://longbridge.com/en/news/287441580.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287441580.md)
generator: "portal-rs"
---

# J.P. Morgan Sticks to Its Buy Rating for First Tracks Biotherapeutics Inc (TRAX)

J.P. Morgan analyst Anupam Rama maintained a Buy rating on First Tracks Biotherapeutics Inc yesterday and set a price target of $30.00. The company’s shares closed yesterday at $17.18.

### Meet Samuel – Your Personal Investing Prophet

-   Start a conversation with TipRanks’ trusted, data-backed investment intelligence
-   Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds

Rama covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Erasca, and Zai Lab. According to TipRanks, Rama has an average return of 21.9% and a 50.20% success rate on recommended stocks. 

Currently, the analyst consensus on First Tracks Biotherapeutics Inc is a Strong Buy with an average price target of $38.33, which is a 123.11% upside from current levels. In a report released on May 15, Barclays also maintained a Buy rating on the stock with a $40.00 price target.

### Related Stocks

- [TRAX.US](https://longbridge.com/en/quote/TRAX.US.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)
- [SRPT.US](https://longbridge.com/en/quote/SRPT.US.md)
- [ERAS.US](https://longbridge.com/en/quote/ERAS.US.md)
- [ZLAB.US](https://longbridge.com/en/quote/ZLAB.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md)
- [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md)
- [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md)
- [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md)
- [8634.JP](https://longbridge.com/en/quote/8634.JP.md)
- [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md)
- [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md)
- [09688.HK](https://longbridge.com/en/quote/09688.HK.md)

## Related News & Research

- [Wolfe Research Begins Coverage on First Tracks Biotherapeutics (NASDAQ:TRAX)](https://longbridge.com/en/news/296233523.md)
- [First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results](https://longbridge.com/en/news/295805215.md)
- [Alliance Global Partners Reaffirms Their Buy Rating on Pelthos Therapeutics (PTHS)](https://longbridge.com/en/news/296781912.md)
- [Maxim Group Reaffirms Their Buy Rating on Our Bond Inc (OBAI)](https://longbridge.com/en/news/296798454.md)
- [Judge rejects First Brands' plan to pay down debts by pursuing lawsuits](https://longbridge.com/en/news/296836223.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**